Share Price and Basic Stock Data
Last Updated: December 13, 2025, 8:08 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Indoco Remedies Ltd operates in the pharmaceutical sector, a field that demands both innovation and resilience. The company’s reported sales have shown a steady upward trajectory, rising from ₹1,541 Cr in FY 2022 to ₹1,669 Cr in FY 2023, and further reaching ₹1,817 Cr in FY 2024. However, the most recent TTM figure stands at ₹1,671 Cr, indicating a slight decline from the previous year. This fluctuation suggests that while Indoco has been able to expand its revenue base over time, it faces challenges in maintaining momentum. Quarterly sales for September 2023 peaked at ₹482 Cr, but subsequent quarters revealed a decline, with ₹450 Cr recorded in March 2024, highlighting potential volatility in demand or operational challenges. Despite these hurdles, the company has a diverse portfolio, which is crucial in the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
The profitability metrics for Indoco Remedies present a mixed picture. The operating profit margin (OPM) has been under pressure, declining from 21% in FY 2022 to just 6% in FY 2025. This shrinking margin indicates rising costs or pricing pressures, which might be a result of increased competition or higher raw material costs. The company recorded a net profit of ₹142 Cr in FY 2023, but this fell dramatically to a loss of ₹78 Cr in FY 2025. Such a reversal is troubling and raises questions about operational efficiency. The interest coverage ratio of 1.58x suggests that while Indoco can cover its interest obligations, the margin for error is slim. Furthermore, with a cash conversion cycle of 232 days, the company’s efficiency in converting investments into cash flow appears stretched, which could impact liquidity in the short term.
Balance Sheet Strength and Financial Ratios
Indoco’s balance sheet reveals both strengths and vulnerabilities. Total borrowings have increased significantly to ₹999 Cr, raising the debt-to-equity ratio to 0.95, which is relatively high and could signal risks associated with leverage. However, the company’s reserves stood at ₹961 Cr, providing a cushion against financial distress. The return on equity (ROE) at 7.02% and return on capital employed (ROCE) at 0.49% appear low, indicating that the company is not generating adequate returns for its shareholders relative to its equity base. The current ratio of 1.24 suggests that Indoco is in a comfortable position to meet its short-term liabilities, but the quick ratio of 0.72 raises concerns about its liquidity if inventory cannot be quickly converted to cash.
Shareholding Pattern and Investor Confidence
Indoco Remedies’ shareholding pattern reflects a stable yet cautious investor sentiment. Promoters hold a substantial 58.90% stake, which indicates confidence in the company’s long-term strategy. However, foreign institutional investors (FIIs) have a minimal presence at 1.25%, suggesting limited international interest or confidence in the stock. Domestic institutional investors (DIIs) hold 18.16%, which is a positive sign, as it reflects institutional confidence, albeit tempered by the declining public shareholding to 21.60%. The total number of shareholders has decreased slightly, from 34,731 in March 2023 to 33,319 in September 2025, indicating some level of disenchantment among retail investors. This mixed sentiment could impact the stock’s liquidity and overall market perception.
Outlook, Risks, and Final Insight
Looking ahead, Indoco Remedies faces a challenging landscape filled with both opportunities and risks. The pharmaceutical sector is poised for growth, but the company must navigate rising costs and competitive pressures to maintain its market share. The declining profitability metrics suggest that operational efficiencies need urgent attention. On the upside, the established brand and diverse product portfolio could provide a buffer against market volatility. However, the high debt levels could pose risks if the company fails to return to profitability. Investors should watch for improvements in operational efficiency and margin recovery as indicators of potential recovery. In conclusion, while Indoco Remedies has a robust foundation, its ability to adapt to market pressures will be crucial in determining its future trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 237/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,250 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,476.95 Cr | 1,156.03 | 52.77 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 408 | 433 | 399 | 428 | 426 | 482 | 459 | 450 | 431 | 433 | 411 | 390 | 438 |
| Expenses | 337 | 345 | 337 | 363 | 365 | 410 | 397 | 401 | 384 | 392 | 399 | 391 | 420 |
| Operating Profit | 71 | 88 | 62 | 65 | 61 | 71 | 63 | 49 | 48 | 40 | 12 | -1 | 18 |
| OPM % | 18% | 20% | 16% | 15% | 14% | 15% | 14% | 11% | 11% | 9% | 3% | -0% | 4% |
| Other Income | 1 | 0 | 0 | 0 | 0 | 4 | -6 | 22 | 1 | 2 | 2 | 2 | 2 |
| Interest | 4 | 5 | 7 | 9 | 8 | 8 | 10 | 12 | 14 | 18 | 16 | 18 | 26 |
| Depreciation | 20 | 16 | 17 | 18 | 20 | 21 | 24 | 26 | 28 | 29 | 29 | 29 | 30 |
| Profit before tax | 48 | 67 | 38 | 39 | 34 | 46 | 23 | 33 | 7 | -5 | -31 | -46 | -37 |
| Tax % | 20% | 26% | 26% | 34% | 29% | 24% | 31% | 33% | 74% | 107% | -8% | -9% | -1% |
| Net Profit | 39 | 50 | 28 | 26 | 24 | 35 | 16 | 22 | 2 | -10 | -28 | -41 | -36 |
| EPS in Rs | 4.19 | 5.40 | 3.05 | 2.80 | 2.65 | 3.81 | 1.77 | 2.46 | 0.28 | -1.04 | -2.86 | -4.38 | -3.88 |
Last Updated: August 1, 2025, 7:20 pm
Below is a detailed analysis of the quarterly data for Indoco Remedies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 438.00 Cr.. The value appears strong and on an upward trend. It has increased from 390.00 Cr. (Mar 2025) to 438.00 Cr., marking an increase of 48.00 Cr..
- For Expenses, as of Jun 2025, the value is 420.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 391.00 Cr. (Mar 2025) to 420.00 Cr., marking an increase of 29.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 19.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears strong and on an upward trend. It has increased from 0.00% (Mar 2025) to 4.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Interest, as of Jun 2025, the value is 26.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 8.00 Cr..
- For Depreciation, as of Jun 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -37.00 Cr.. The value appears strong and on an upward trend. It has increased from -46.00 Cr. (Mar 2025) to -37.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Jun 2025, the value is -1.00%. The value appears to be increasing, which may not be favorable. It has increased from -9.00% (Mar 2025) to -1.00%, marking an increase of 8.00%.
- For Net Profit, as of Jun 2025, the value is -36.00 Cr.. The value appears strong and on an upward trend. It has increased from -41.00 Cr. (Mar 2025) to -36.00 Cr., marking an increase of 5.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.88. The value appears strong and on an upward trend. It has increased from -4.38 (Mar 2025) to -3.88, marking an increase of 0.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 731 | 854 | 1,005 | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,671 |
| Expenses | 610 | 689 | 834 | 914 | 906 | 892 | 983 | 1,017 | 1,213 | 1,381 | 1,572 | 1,565 | 1,602 |
| Operating Profit | 120 | 166 | 171 | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 100 | 69 |
| OPM % | 16% | 19% | 17% | 15% | 13% | 8% | 11% | 18% | 21% | 17% | 13% | 6% | 4% |
| Other Income | 2 | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 1 | 20 | 6 | 7 |
| Interest | 19 | 11 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 | 38 | 66 | 78 |
| Depreciation | 31 | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 | 92 | 114 | 116 |
| Profit before tax | 72 | 110 | 99 | 91 | 48 | -9 | 29 | 132 | 237 | 193 | 136 | -74 | -118 |
| Tax % | 20% | 24% | 17% | 15% | 15% | -69% | 16% | 30% | 35% | 26% | 29% | 5% | |
| Net Profit | 58 | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -116 |
| EPS in Rs | 6.29 | 8.99 | 8.89 | 8.36 | 4.47 | -0.31 | 2.62 | 10.10 | 16.80 | 15.44 | 10.68 | -7.99 | -12.16 |
| Dividend Payout % | 22% | 18% | 18% | 19% | 22% | -95% | 11% | 15% | 13% | 15% | 14% | -2% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 43.10% | -1.20% | -6.10% | -46.75% | -107.32% | 900.00% | 287.50% | 66.67% | -8.39% | -31.69% | -180.41% |
| Change in YoY Net Profit Growth (%) | 0.00% | -44.31% | -4.89% | -40.66% | -60.56% | 1007.32% | -612.50% | -220.83% | -75.05% | -23.30% | -148.72% |
Indoco Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 3% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -263% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 5% |
| 3 Years: | -10% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| Last Year: | -7% |
Last Updated: September 5, 2025, 7:25 am
Balance Sheet
Last Updated: December 4, 2025, 1:25 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| Reserves | 439 | 500 | 558 | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,091 | 1,004 | 961 |
| Borrowings | 92 | 97 | 140 | 280 | 282 | 296 | 262 | 267 | 257 | 333 | 672 | 994 | 999 |
| Other Liabilities | 180 | 230 | 224 | 266 | 281 | 301 | 330 | 279 | 325 | 297 | 363 | 414 | 530 |
| Total Liabilities | 729 | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,508 |
| Fixed Assets | 325 | 340 | 374 | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 | 997 | 1,143 |
| CWIP | 44 | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 | 321 | 182 |
| Investments | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 1 | 1 |
| Other Assets | 360 | 443 | 496 | 666 | 613 | 605 | 631 | 677 | 809 | 864 | 1,057 | 1,111 | 1,182 |
| Total Assets | 729 | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,508 |
Below is a detailed analysis of the balance sheet data for Indoco Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
- For Reserves, as of Sep 2025, the value is 961.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,004.00 Cr. (Mar 2025) to 961.00 Cr., marking a decrease of 43.00 Cr..
- For Borrowings, as of Sep 2025, the value is 999.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 994.00 Cr. (Mar 2025) to 999.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 530.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 414.00 Cr. (Mar 2025) to 530.00 Cr., marking an increase of 116.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,508.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,430.00 Cr. (Mar 2025) to 2,508.00 Cr., marking an increase of 78.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,143.00 Cr.. The value appears strong and on an upward trend. It has increased from 997.00 Cr. (Mar 2025) to 1,143.00 Cr., marking an increase of 146.00 Cr..
- For CWIP, as of Sep 2025, the value is 182.00 Cr.. The value appears to be declining and may need further review. It has decreased from 321.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 139.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,182.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,111.00 Cr. (Mar 2025) to 1,182.00 Cr., marking an increase of 71.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,508.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,430.00 Cr. (Mar 2025) to 2,508.00 Cr., marking an increase of 78.00 Cr..
However, the Borrowings (999.00 Cr.) are higher than the Reserves (961.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 28.00 | 69.00 | 31.00 | -123.00 | -147.00 | -219.00 | -139.00 | -42.00 | 71.00 | -45.00 | -427.00 | -894.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 69 | 66 | 69 | 74 | 73 | 74 | 69 | 69 | 70 | 77 | 82 | 77 |
| Inventory Days | 148 | 181 | 174 | 189 | 203 | 209 | 230 | 245 | 248 | 228 | 230 | 307 |
| Days Payable | 95 | 146 | 137 | 166 | 157 | 195 | 183 | 117 | 107 | 86 | 100 | 152 |
| Cash Conversion Cycle | 122 | 102 | 105 | 97 | 119 | 88 | 116 | 197 | 212 | 219 | 212 | 232 |
| Working Capital Days | 44 | 46 | 48 | 41 | 38 | 21 | 22 | 59 | 78 | 82 | 62 | 39 |
| ROCE % | 17% | 21% | 17% | 12% | 7% | 1% | 6% | 16% | 23% | 17% | 10% | -0% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 4,199,230 | 0.38 | 117.22 | 4,199,230 | 2025-04-22 17:25:31 | 0% |
| DSP Healthcare Fund | 3,233,474 | 2.87 | 90.26 | 2,275,954 | 2025-12-08 05:54:26 | 42.07% |
| Nippon India Small Cap Fund | 2,594,559 | 0.11 | 72.43 | 2,744,559 | 2025-12-08 05:54:26 | -5.47% |
| Franklin India Small Cap Fund | 2,025,592 | 0.41 | 56.54 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 1,834,924 | 0.61 | 51.22 | 1,834,924 | 2025-04-22 17:25:31 | 0% |
| HDFC Value Fund | 1,534,403 | 0.56 | 42.83 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | -8.46 | 10.53 | 15.44 | 16.80 | 10.10 |
| Diluted EPS (Rs.) | -8.45 | 10.51 | 15.42 | 16.80 | 10.10 |
| Cash EPS (Rs.) | 3.89 | 20.49 | 23.10 | 25.37 | 18.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 110.79 | 120.47 | 111.58 | 98.17 | 83.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 110.79 | 120.47 | 111.58 | 98.17 | 83.45 |
| Revenue From Operations / Share (Rs.) | 180.48 | 197.14 | 181.07 | 167.20 | 134.73 |
| PBDIT / Share (Rs.) | 11.35 | 27.57 | 31.30 | 35.77 | 24.68 |
| PBIT / Share (Rs.) | -0.99 | 17.61 | 23.64 | 27.21 | 16.74 |
| PBT / Share (Rs.) | -8.06 | 14.73 | 20.92 | 25.67 | 14.32 |
| Net Profit / Share (Rs.) | -8.45 | 10.52 | 15.44 | 16.80 | 10.10 |
| NP After MI And SOA / Share (Rs.) | -7.99 | 10.68 | 15.44 | 16.80 | 10.10 |
| PBDIT Margin (%) | 6.28 | 13.98 | 17.28 | 21.39 | 18.31 |
| PBIT Margin (%) | -0.54 | 8.93 | 13.05 | 16.27 | 12.42 |
| PBT Margin (%) | -4.46 | 7.47 | 11.55 | 15.35 | 10.63 |
| Net Profit Margin (%) | -4.68 | 5.33 | 8.52 | 10.04 | 7.49 |
| NP After MI And SOA Margin (%) | -4.42 | 5.41 | 8.52 | 10.04 | 7.49 |
| Return on Networth / Equity (%) | -7.21 | 8.87 | 13.83 | 17.11 | 12.09 |
| Return on Capital Employeed (%) | -0.56 | 10.59 | 17.65 | 23.62 | 16.98 |
| Return On Assets (%) | -3.03 | 4.59 | 8.57 | 10.41 | 7.07 |
| Long Term Debt / Equity (X) | 0.52 | 0.31 | 0.13 | 0.10 | 0.12 |
| Total Debt / Equity (X) | 0.95 | 0.59 | 0.30 | 0.26 | 0.27 |
| Asset Turnover Ratio (%) | 0.72 | 0.95 | 1.06 | 1.10 | 0.95 |
| Current Ratio (X) | 1.24 | 1.56 | 1.90 | 1.82 | 1.53 |
| Quick Ratio (X) | 0.72 | 0.98 | 1.14 | 1.09 | 0.94 |
| Inventory Turnover Ratio (X) | 4.31 | 1.43 | 1.29 | 1.44 | 1.36 |
| Dividend Payout Ratio (NP) (%) | -18.75 | 21.05 | 14.57 | 8.92 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 34.47 | 10.89 | 9.74 | 5.91 | 0.00 |
| Earning Retention Ratio (%) | 118.75 | 78.95 | 85.43 | 91.08 | 0.00 |
| Cash Earning Retention Ratio (%) | 65.53 | 89.11 | 90.26 | 94.09 | 0.00 |
| Interest Coverage Ratio (X) | 1.58 | 6.68 | 11.52 | 23.31 | 10.21 |
| Interest Coverage Ratio (Post Tax) (X) | -0.19 | 3.25 | 6.68 | 11.95 | 5.18 |
| Enterprise Value (Cr.) | 3109.49 | 3659.62 | 3301.12 | 3694.36 | 2857.47 |
| EV / Net Operating Revenue (X) | 1.87 | 2.01 | 1.98 | 2.40 | 2.30 |
| EV / EBITDA (X) | 29.70 | 14.40 | 11.45 | 11.21 | 12.57 |
| MarketCap / Net Operating Revenue (X) | 1.29 | 1.67 | 1.80 | 2.25 | 2.14 |
| Retention Ratios (%) | 118.75 | 78.94 | 85.42 | 91.07 | 0.00 |
| Price / BV (X) | 2.11 | 2.73 | 2.92 | 3.84 | 3.46 |
| Price / Net Operating Revenue (X) | 1.29 | 1.67 | 1.80 | 2.25 | 2.14 |
| EarningsYield | -0.03 | 0.03 | 0.04 | 0.04 | 0.03 |
After reviewing the key financial ratios for Indoco Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.46. This value is below the healthy minimum of 5. It has decreased from 10.53 (Mar 24) to -8.46, marking a decrease of 18.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is -8.45. This value is below the healthy minimum of 5. It has decreased from 10.51 (Mar 24) to -8.45, marking a decrease of 18.96.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.89. This value is within the healthy range. It has decreased from 20.49 (Mar 24) to 3.89, marking a decrease of 16.60.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 110.79. It has decreased from 120.47 (Mar 24) to 110.79, marking a decrease of 9.68.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 110.79. It has decreased from 120.47 (Mar 24) to 110.79, marking a decrease of 9.68.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 180.48. It has decreased from 197.14 (Mar 24) to 180.48, marking a decrease of 16.66.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.35. This value is within the healthy range. It has decreased from 27.57 (Mar 24) to 11.35, marking a decrease of 16.22.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.99. This value is below the healthy minimum of 0. It has decreased from 17.61 (Mar 24) to -0.99, marking a decrease of 18.60.
- For PBT / Share (Rs.), as of Mar 25, the value is -8.06. This value is below the healthy minimum of 0. It has decreased from 14.73 (Mar 24) to -8.06, marking a decrease of 22.79.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -8.45. This value is below the healthy minimum of 2. It has decreased from 10.52 (Mar 24) to -8.45, marking a decrease of 18.97.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.99. This value is below the healthy minimum of 2. It has decreased from 10.68 (Mar 24) to -7.99, marking a decrease of 18.67.
- For PBDIT Margin (%), as of Mar 25, the value is 6.28. This value is below the healthy minimum of 10. It has decreased from 13.98 (Mar 24) to 6.28, marking a decrease of 7.70.
- For PBIT Margin (%), as of Mar 25, the value is -0.54. This value is below the healthy minimum of 10. It has decreased from 8.93 (Mar 24) to -0.54, marking a decrease of 9.47.
- For PBT Margin (%), as of Mar 25, the value is -4.46. This value is below the healthy minimum of 10. It has decreased from 7.47 (Mar 24) to -4.46, marking a decrease of 11.93.
- For Net Profit Margin (%), as of Mar 25, the value is -4.68. This value is below the healthy minimum of 5. It has decreased from 5.33 (Mar 24) to -4.68, marking a decrease of 10.01.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -4.42. This value is below the healthy minimum of 8. It has decreased from 5.41 (Mar 24) to -4.42, marking a decrease of 9.83.
- For Return on Networth / Equity (%), as of Mar 25, the value is -7.21. This value is below the healthy minimum of 15. It has decreased from 8.87 (Mar 24) to -7.21, marking a decrease of 16.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 10. It has decreased from 10.59 (Mar 24) to -0.56, marking a decrease of 11.15.
- For Return On Assets (%), as of Mar 25, the value is -3.03. This value is below the healthy minimum of 5. It has decreased from 4.59 (Mar 24) to -3.03, marking a decrease of 7.62.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.52. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.52, marking an increase of 0.21.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has increased from 0.59 (Mar 24) to 0.95, marking an increase of 0.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has decreased from 0.95 (Mar 24) to 0.72, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 1.5. It has decreased from 1.56 (Mar 24) to 1.24, marking a decrease of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 0.72. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.72, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.31. This value is within the healthy range. It has increased from 1.43 (Mar 24) to 4.31, marking an increase of 2.88.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -18.75. This value is below the healthy minimum of 20. It has decreased from 21.05 (Mar 24) to -18.75, marking a decrease of 39.80.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 34.47. This value is within the healthy range. It has increased from 10.89 (Mar 24) to 34.47, marking an increase of 23.58.
- For Earning Retention Ratio (%), as of Mar 25, the value is 118.75. This value exceeds the healthy maximum of 70. It has increased from 78.95 (Mar 24) to 118.75, marking an increase of 39.80.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 65.53. This value is within the healthy range. It has decreased from 89.11 (Mar 24) to 65.53, marking a decrease of 23.58.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 3. It has decreased from 6.68 (Mar 24) to 1.58, marking a decrease of 5.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 3. It has decreased from 3.25 (Mar 24) to -0.19, marking a decrease of 3.44.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,109.49. It has decreased from 3,659.62 (Mar 24) to 3,109.49, marking a decrease of 550.13.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.87, marking a decrease of 0.14.
- For EV / EBITDA (X), as of Mar 25, the value is 29.70. This value exceeds the healthy maximum of 15. It has increased from 14.40 (Mar 24) to 29.70, marking an increase of 15.30.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.29. This value is within the healthy range. It has decreased from 1.67 (Mar 24) to 1.29, marking a decrease of 0.38.
- For Retention Ratios (%), as of Mar 25, the value is 118.75. This value exceeds the healthy maximum of 70. It has increased from 78.94 (Mar 24) to 118.75, marking an increase of 39.81.
- For Price / BV (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 2.11, marking a decrease of 0.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.29. This value is within the healthy range. It has decreased from 1.67 (Mar 24) to 1.29, marking a decrease of 0.38.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to -0.03, marking a decrease of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indoco Remedies Ltd:
- Net Profit Margin: -4.68%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.56% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -7.21% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.19
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.95
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -4.68%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Indoco House, 166, CST Road, Kalina, Mumbai Maharashtra 400098 | compliance.officer@indoco.com http://www.indoco.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suresh G Kare | Chairman |
| Ms. Aditi Panandikar | Managing Director |
| Mr. Sundeep V Bambolkar | Joint Managing Director |
| Dr. Anand Nadkarni | Non Executive Director |
| Mr. Satish Shenoy | Independent Director |
| Mr. Ajay Mulgaokar | Independent Director |
| Dr.(Ms.) Vasudha V Kamat | Independent Director |
| Mr. Abhijit Y Gore | Independent Director |
FAQ
What is the intrinsic value of Indoco Remedies Ltd?
Indoco Remedies Ltd's intrinsic value (as of 13 December 2025) is 89.37 which is 63.22% lower the current market price of 243.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,237 Cr. market cap, FY2025-2026 high/low of 350/190, reserves of ₹961 Cr, and liabilities of 2,508 Cr.
What is the Market Cap of Indoco Remedies Ltd?
The Market Cap of Indoco Remedies Ltd is 2,237 Cr..
What is the current Stock Price of Indoco Remedies Ltd as on 13 December 2025?
The current stock price of Indoco Remedies Ltd as on 13 December 2025 is 243.
What is the High / Low of Indoco Remedies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Indoco Remedies Ltd stocks is 350/190.
What is the Stock P/E of Indoco Remedies Ltd?
The Stock P/E of Indoco Remedies Ltd is .
What is the Book Value of Indoco Remedies Ltd?
The Book Value of Indoco Remedies Ltd is 106.
What is the Dividend Yield of Indoco Remedies Ltd?
The Dividend Yield of Indoco Remedies Ltd is 0.08 %.
What is the ROCE of Indoco Remedies Ltd?
The ROCE of Indoco Remedies Ltd is 0.49 %.
What is the ROE of Indoco Remedies Ltd?
The ROE of Indoco Remedies Ltd is 7.02 %.
What is the Face Value of Indoco Remedies Ltd?
The Face Value of Indoco Remedies Ltd is 2.00.